FDA approves Zinbryta for MS

FDA approved Zinbryta daclizumab from Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc. (NASDAQ:ABBV) to treat relapsing forms of multiple sclerosis in adults. The drug is a humanized IgG1 mAb against IL-2 receptor alpha chain ( CD25).

Distribution of Zinbryta will be limited by a REMS, and its label will have a black box warning about risks of severe liver injury and immune disorders including non-infectious colitis, skin reactions and lymphadenopathy. ...